Skip to main content

Table 2 Summary of VTE and Major Bleeding Rates in Trials Comparing Extended-Duration Thromboprophylaxis Strategies in Cancer Patients

From: The potential benefits of low-molecular-weight heparins in cancer patients

Ref. Cancer Patients, N Drug VTE Detection VTE, % Bleeding*, %
[48] Gastrointestinal, genitourinary, gynecological 167 Enoxaparin 40 mg SC 6--10 days plus placebo 19--21 days Symptomatic and asymptomatic VTE: DVT - venography; PE - VPS, pulmonary angiography 12 3.6 (minor)
3.6 (major)
   165 Enoxaparin 40 mg SC 25--31 days   4.8 4.7 (minor)
5.1 (major)
[49] Abdominal (all patients) 178 Dalteparin 5,000 IU OD plus GCS for 7 days Symptomatic and asymptomatic VTE: DVT - venography; PE - VPS, spiral computerized tomography, autopsy 16.3 0.9 (minor)
1.8 (major)
   165 Dalteparin 5,000 IU SC OD plus GCS for 7 days, plus further 21 days   7.3 1.5 (minor)
0.5 (major)
[50] Abdominal cancer sub-group 198 total Dalteparin 5,000 IU OD plus GCS for 7 days   19.6
proximal DVT: 10.4
Not reported
    Dalteparin 5,000 IU SC OD plus GCS for 7 days, plus further 21 days   8.8
proximal DVT: 2.2
 
  1. DVT, deep vein thrombosis; GCS, graduated compression stockings; OD, once daily; PE, pulmonary embolism; SC, subcutaneous; VPS; ventilation perfusion scan; VTE, venous thromboembolism.
  2. * For definitions of major bleeding see original studies.
  3. Included non-cancer patients